CTT Pharma Strengthens Caffeine Patent in USA | News Direct

CTT Pharma Strengthens Caffeine Patent in USA

News release by CTT Pharmaceutical Holdings Inc

facebook icon linkedin icon twitter icon pinterest icon email icon Ottawa, Ontario | April 27, 2022 07:01 AM Eastern Daylight Time

CTT Pharmaceutical Holdings Inc
CTT Pharmaceutical Holdings Inc
 

 Tampa, Florida, United States - TheNewswire  - April 27, 2022 - CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) is announcing today that we have recently filed a patent application encompassing Caffeine-containing orally administrable strips. The continuation-in-part application stems from our previously granted US Patent for similar orally administrable strips and is based on technology already determined to be patentable by the United States Patent and Trademark Office. The strips have been developed to deliver caffeine for absorption by the oral mucosa. This patent covers dissolvable strips containing caffeine from various sources.  

 

 CTT Pharma’s caffeine strips dissolve in your mouth in seconds, then enters the bloodstream, bypassing the digestive tract including the liver. This allows for fast onset, better absorption/bioavailability, and the ability to add/combine actives to our Caffeine strips, such as CBD, and B12 for example. CTT can also make our strips with any color and any flavor.  

 

 “Unlike coffee and energy drinks which has many competitors, energy strips in the US are an untapped market. This helped with my decision to strengthen our caffeine patents. CTT will look to monetize this patent pending technology with a company looking to enter into the caffeine/energy strip market in the United States.” said Ryan Khouri, CEO of CTT Pharma.  

 

 CTT Pharma will continue to update our shareholders as more news becomes available.  

  

 Ryan Khouri - 813-606-0060  

 

 www.linkedin.com/in/ryan-khouri-679a251b7 

 

 www.cttpharmaceuticals.com